UBS Group
HRTX icon

UBS Group’s Heron Therapeutics HRTX Stock Holding History

UBS Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.83M Buy
2,285,883
+194,214
+9% +$225K ﹤0.01% 5056
2025
Q4 		$2.72M Sell
2,091,669
-842,412
-29% -$1.04M ﹤0.01% 4671
2025
Q3 		$3.7M Sell
2,934,081
-250,884
-8% -$398K ﹤0.01% 4347
2025
Q2 		$6.59M Buy
3,184,965
+3,026,226
+1,906% +$6.18M ﹤0.01% 3582
2025
Q1 		$349K Sell
158,739
-737
-0.5% -$1.43K ﹤0.01% 6127
2024
Q4 		$244K Buy
159,476
+74,223
+87% +$120K ﹤0.01% 6332
2024
Q3 		$170K Sell
85,253
-81,540
-49% -$195K ﹤0.01% 5998
2024
Q2 		$584K Buy
166,793
+55,399
+50% +$170K ﹤0.01% 4890
2024
Q1 		$309K Sell
111,394
-10,082
-8% -$25.3K ﹤0.01% 5547
2023
Q4 		$207K Buy
121,476
+58,410
+93% +$64.3K ﹤0.01% 5761
2023
Q3 		$65K Sell
63,066
-5,971
-9% -$8.5K ﹤0.01% 6122
2023
Q2 		$80.1K Buy
69,037
+13,269
+24% +$23.7K ﹤0.01% 6181
2023
Q1 		$84.2K Buy
55,768
+18,875
+51% +$47.3K ﹤0.01% 6047
2022
Q4 		$92.2K Sell
36,893
-50,994
-58% -$164K ﹤0.01% 6184
2022
Q3 		$372K Buy
87,887
+79,826
+990% +$312K ﹤0.01% 4589
2022
Q2 		$22K Sell
8,061
-226,059
-97% -$908K ﹤0.01% 6762
2022
Q1 		$1.34M Sell
234,120
-85,137
-27% -$623K ﹤0.01% 3819
2021
Q4 		$2.92M Buy
319,257
+71,149
+29% +$726K ﹤0.01% 3386
2021
Q3 		$2.65M Buy
248,108
+239,993
+2,957% +$2.92M ﹤0.01% 3332
2021
Q2 		$126K Sell
8,115
-139,789
-95% -$2.22M ﹤0.01% 5704
2021
Q1 		$2.4M Buy
147,904
+16,454
+13% +$293K ﹤0.01% 3379
2020
Q4 		$2.78M Buy
131,450
+39,866
+44% +$693K ﹤0.01% 3067
2020
Q3 		$1.36M Sell
91,584
-22,795
-20% -$356K ﹤0.01% 3412
2020
Q2 		$1.68M Sell
114,379
-10,941
-9% -$180K ﹤0.01% 3034
2020
Q1 		$1.47M Buy
125,320
+26,784
+27% +$503K ﹤0.01% 3040
2019
Q4 		$2.31M Sell
98,536
-142,312
-59% -$3.15M ﹤0.01% 3407
2019
Q3 		$4.46M Buy
240,848
+61,140
+34% +$1.13M ﹤0.01% 2496
2019
Q2 		$3.34M Buy
179,708
+122,805
+216% +$2.45M ﹤0.01% 2674
2019
Q1 		$1.39M Sell
56,903
-148,476
-72% -$3.89M ﹤0.01% 3310
2018
Q4 		$5.33M Buy
205,379
+118,661
+137% +$3.26M ﹤0.01% 2092
2018
Q3 		$2.75M Buy
86,718
+34,942
+67% +$1.3M ﹤0.01% 2915
2018
Q2 		$2.01M Sell
51,776
-167,024
-76% -$5.32M ﹤0.01% 3164
2018
Q1 		$6.04M Buy
218,800
+179,364
+455% +$4.07M ﹤0.01% 2133
2017
Q4 		$714K Sell
39,436
-6,047
-13% -$98.6K ﹤0.01% 4034
2017
Q3 		$734K Buy
45,483
+14,963
+49% +$235K ﹤0.01% 3940
2017
Q2 		$423K Buy
30,520
+18,966
+164% +$275K ﹤0.01% 4233
2017
Q1 		$173K Sell
11,554
-33,102
-74% -$458K ﹤0.01% 4730
2016
Q4 		$585K Buy
44,656
+35,686
+398% +$560K ﹤0.01% 3989
2016
Q3 		$155K Sell
8,970
-197,002
-96% -$3.66M ﹤0.01% 4719
2016
Q2 		$3.72M Buy
205,972
+66,349
+48% +$1.3M ﹤0.01% 2233
2016
Q1 		$2.65M Sell
139,623
-211,584
-60% -$4.17M ﹤0.01% 2417
2015
Q4 		$9.38M Buy
351,207
+39,978
+13% +$1.07M 0.01% 1447
2015
Q3 		$7.59M Buy
311,229
+70,179
+29% +$2.34M 0.01% 1598
2015
Q2 		$7.51M Buy
241,050
+239,612
+16,663% +$4.51M 0.01% 1706
2015
Q1 		$21K Sell
1,438
-165
-10% -$1.86K ﹤0.01% 6939
2014
Q4 		$16K Buy
+1,603
New +$13.1K ﹤0.01% 7958

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.29B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return